Andrew Bass 9/11/26 Andrew Bass 9/11/26

NATURE BIOTECHNOLOGY HIGHLIGHTS RYBODYN AT THE FRONTIER OF DARK PROTEOME DRUG DISCOVERY

Nature Biotechnology highlights RyboDyn at the frontier of dark proteome drug discovery.

Andrew Bass 8/12/26 Andrew Bass 8/12/26

RYBODYN UNVEILS A HIDDEN HUMAN PROTEOME AND A NEW UNIVERSE OF ACTIONABLE CANCER TARGETS

RyboDyn Unveils a Hidden Human Proteome and a New Universe of Actionable Cancer Targets.

Andrew Bass 7/9/26 Andrew Bass 7/9/26

RyboDyn awarded $1.3M DOW grant to advance novel antibody therapies for lung cancer.

Andrew Bass 3/24/26 Andrew Bass 3/24/26

RyboDyn announces Seed financing to advance AI-driven discovery of hidden cancer targets.

Andrew Bass 1/27/26 Andrew Bass 1/27/26

RyboDyn Joins NVIDIA Inception to Advance AI-Powered Discovery of the Dark Proteome.

Andrew Bass 9/29/25 Andrew Bass 9/29/25

RyboDyn is honored to be featured in the San Diego Union-Tribune for Lilly and Company Gateway Labs opening.

Andrew Bass 6/19/25 Andrew Bass 6/19/25

Lilly Collaboration Accelerates RyboDyn’s Dark Proteome Targets Toward First-in-Class Therapies

Andrew Bass 5/15/25 Andrew Bass 5/15/25

RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center

Andrew Bass 1/9/25 Andrew Bass 1/9/25

RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing